Patients with chronic kidney disease who had hypertension and diabetes and received insulin therapy showed a 35% lower risk ...

While the renal benefits of oral semaglutide vs placebo in the SOUL trial didn't match the effects seen with the injectable ...

GLP-1 drugs show promise in diabetes management, offering heart and kidney benefits, but also highlight the need for ...

Novo Nordisk NVO shares have gained 5.8% in a week. The uptrend in the stock price was driven by reports of an activist hedge ...